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Abstract 
Review on NR5A1, with data on DNA/RNA, on the 
protein encoded and where the gene is implicated. 
Identity 
Other names: AD4BP, ELP, FTZ1, FTZF1, POF7, 
SF-1, SF1, SPGF8, SRXY3 
HGNC (Hugo): NR5A1 
Location: 9q33.3 
Note: Steroidogenic factor-1 (SF-1) is an orphan 
member of the nuclear receptor superfamily which 
acts as a key regulator of adrenogonadal 
development and tissue-specific gene expression in 
steroidogenic cells. Parker's and Morohashi's groups 
identified SF-1 by its capacity to activate 
transcription from multiple P450 steroidogenic 
enzyme promoters (Lala et al., 1992; Morohashi et 
al., 1992). Besides its recognized role as a master 
regulator of steroidogenesis in the adrenal cortex and 
gonads, recent studies indicate that the regulation of 
gene expression in the adrenal cortex by SF-1 also 
involves processes other than steroidogenesis 
(reviewed in Lalli et al., 2013). 
DNA/RNA 
In 1992 the mouse Sf-1 gene (Nr5a1) was cloned 
from an adrenal cDNA library using a probe 
corresponding to the DNA-binding domain (DBD) 
of the related orphan receptor retinoid X receptor 
(Lala et al., 1992).  
Later, its bovine homologue (called adrenal 4-
binding protein, Ad4BP) was identified from an 
adrenal cDNA library exploiting the partial sequence 
of a protein purified from bovine adrenal extracts 
(Honda et al., 1993). The proteins encoded by both 
these murine and bovine cDNAs were able to 
activate promoters of steroid hydroxylase enzymes, 
indicating that a common steroidogenic factor had 
been identified. Initially the mouse gene encoding 
SF-1 was called FtzF1, similar to the Drosophila 
orphan nuclear receptor fushi tarazu factor homolog 
1 (FTZ-F1) and mapped to chromosome 2 (Ueda et 
al., 1990; Swift and Ashworth, 1995; Taketo et al., 
1995).  
The corresponding human SF-1 gene was initially 
termed FTZF1 and later NR5A1 (see above) 
according to the standard nomenclature system for 
nuclear receptors. 
Figure 1. NR5A1 chromosomal localization. The NR5A1 gene maps on chromosome 9q33.3 (adapted from GeneCards). 
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Figure 2. Structure of the SF-1 protein. SF-1 contains the major structural features present in all nuclear receptors. N, N-
terminus of the protein; DBD, DNA binding domain with two zinc finger (ZnI and ZnII) motifs; Ftz-F1, Fushi-tarazu-F1 domain with 
a nuclear localization signal (NLS); Hinge, hinge region displaying a Pro-rich (proline-rich) region and an AF-1- (transcriptional 
activation domain 1) like domain; LBD, ligand-binding domain; AF-2, transcriptional activation domain 2; C, C-terminus of the 
protein. 
 
Description 
Size: 26.18 Kb (GeneCards), 7 exons. mRNA: 3095 
bp (NM_004959). 
Transcription 
The human NR5A1 gene is mapped to the long arm 
of chromosome 9 (9q33, Figure 1) and consists of 7 
exons spanning approximately 27 Kb of genomic 
DNA (Taketo et al., 1995; Oba et al., 1996; Wong et 
al., 1996). Exon 1 is untranslated. 
Protein 
Description 
The SF-1 protein contains the typical domains of 
other members of the nuclear receptor superfamily ( 
NURSA): an N-terminal DBD including two zinc 
fingers, a flexible proline-rich hinge region 
displaying AF-1 - like activation activity, a ligand 
binding domain (LBD) and a C-terminal AF-2 
activation domain, which is required for 
transcriptional activity and cofactor interactions 
(Figure 2). 
A proximal (P) box implicated in the specific 
recognition of DNA target sequences by nuclear 
receptors has been described in the first zinc finger 
of SF-1 DBD. This sequence interacts with the 
hormone response element core in the major groove 
of the DNA helix by recognizing variations on the 
AGGTCA motif (Evans, 1998). SF-1 also exhibits a 
FTZ-F1 box or A box, which represents a 30-
aminoacid extension of the DBD, being important 
for DNA anchoring. Indeed, at variance from most 
nuclear receptors, SF-1 binds to target genes 
monomerically rather than as a homo- or 
heterodimer and with highest affinity to 
5'YCAAGGYCR'3 (where Y= T/C; R= G/A) (Ueda 
and Hirose, 1991; Wilson et al., 1993). X-ray 
crystallography of the SF-1 DBD complexed with a 
sequence in the inhibin-α gene proximal promoter 
region has shown that the A-box primarily interacts 
with the 5' flanking sequence and the first part of the 
half site in the minor groove of DNA (Ito et al., 
2000a; Little et al., 2006). Moreover, the same study 
revealed that SF-1 displays a helix in the C-terminal 
segment of the FTZ-F1 box which interacts with 
both the core DBD and the DNA, thus acting as an 
important determinant of the complex stability 
(Little et al., 2006). It has been proposed that this 
helix may also serve as a platform for coactivators 
and other DNA-bound factors interaction (Little et 
al., 2006). 
The hinge region, which lies between the N-terminal 
DBD and the C-terminal LBD is more than a flexible 
connector between the LBD and the DBD. It 
participates in conjunction with helix 1 (H1, see 
below) to promote an active protein conformation 
(Desclozeaux et al., 2002). Furthermore, it is 
important for post-transcriptional/translational 
modifications, like phosphorylation and 
SUMOylation (Hammer et al., 1999; Komatsu et al., 
2004; Lee et al., 2005; Lewis et al., 2008). In 
particular, phosphorylation of the hinge region 
enhances SF-1 overall stability and transcriptional 
activity (Desclozeaux et al., 2002). 
The LBD contains 12 helices (H1-H12, like other 
nuclear receptors), that can form an AF2 domain for 
the recruitment of cofactors. SF-1 has been 
considered as an "orphan" nuclear receptor for many 
years because of the absence of high-affinity 
naturally occurring ligands identified. This led to the 
hypothesis that the LBD of SF-1 could adopt a stable 
conformation in the absence of ligand (Desclozeaux 
et al., 2002). Later, different groups have been able 
to crystallize the SF-1 LBD, showing that small 
phospholipids ligands (e.g. phosphatidylinositols) 
can bind to this domain (Krylova et al., 2005; Li et 
al., 2005; Wang et al., 2005). 
Protein translation: 
MDYSYDEDLD ELCPVCGDKV SGYHYGLLTC 
ESCKGFFKRT VQNNKHYTCT ESQSCKIDKT 
QRKRCPFCRF QKCLTVGMRL 
EAVRADRMRG GRNKFGPMYK 
RDRALKQQKK AQIRANGFKL ETGPPMGVPP 
PPPPAPDYVL PPSLHGPEPK GLAAGPPAGP 
LGDFGAPALP MAVPGAHGPL AGYLYPAFPG 
RAIKSEYPEP YASPPQPGLP YGYPEPFSGG 
PNVPELILQL LQLEPDEDQV RARILGCLQE 
PTKSRPDQPA AFGLLCRMAD QTFISIVDWA 
RRCMVFKELE VADQMTLLQN 
CWSELLVFDH IYRQVQHGKE GSILLVTGQE 
VELTTVATQA GSLLHSLVLR AQELVLQLLA 
LQLDRQEFVC LKFIILFSLD LKFLNNHILV 
KDAQEKANAA LLDYTLCHYP 
HCGDKFQQLL LCLVEVRALS 
MQAKEYLYHK HLGNEMPRNN 
LLIEMLQAKQ T 
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Sequence length: 461 aa; Molecular weight: 51,636 
kDa 
Expression 
SF-1 localization in adult tissues has been widely 
investigated in mice, rats, human and other 
vertebrates. Its expression pattern is consistent with 
its role as a steroidogenesis master regulator and is 
strikingly overlapping with that of another nuclear 
receptor, Dax-1 (Nr0b1) (Ikeda et al., 1996; Swain et 
al., 1996; Tamai et al., 1996; Ikeda et al., 2001), 
which functions as a negative regulator of SF-1 
activity. SF-1 is expressed in tissues involved in 
steroid hormone production and reproductive 
function, i.e. the three layers of the adrenal cortex, 
testicular Leydig and Sertoli cells, ovarian 
interstitium, theca and granulosa cells, and, to a 
lesser degree, corpus luteum (Honda et al., 1993; 
Ikeda et al., 1993; Morohashi et al., 1994; Ramayya 
et al., 1997; Morohashi, 1999). SF-1 is also 
expressed in non-steroidogenic tissues like pituitary 
gonadotropes. It is also expressed in the dorsomedial 
portion of the ventromedial hypothalamus (VMH) 
(Ikeda et al., 1994; Shinoda et al., 1995), in the 
endothelial linings of the venous sinuses and pulp 
veins in the spleen (Ramayya et al., 1997; Morohashi 
et al., 1999), and in a subset of hippocampal neurons. 
It has been described that in developing human 
embryos SF-1 represents the earliest marker of 
adrenogonadal differentiation, first appearing in the 
urogenital ridge (Ikeda et al., 1994; Morohashi et al., 
1995; Hanley et al., 1999; Hanley et al., 2001). 
In the mouse, SF-1 is first expressed at embryonic 
day 9 (E9.0) in the adrenal/gonadal primordium 
(AGP) (Hatano et al., 1996). After gonadal and 
adrenal anlagen separation at E11.0, SF-1 is 
expressed throughout gestation in the developing 
steroidogenic adrenal portion and in zona 
glomerulosa, fasciculata and reticularis of the adult 
gland. In contrast, it is not expressed in the neural 
crest cells that migrate to the medulla during 
development (Ikeda et al., 1994) nor in the adult 
medulla (Ikeda et al., 1993). While SF-1 is expressed 
in the indifferent gonad, it displays a sexually 
dimorphic expression pattern in the developing testis 
and ovaries (Ikeda et al., 1994). Indeed, it disappears 
from the ovaries between E13.5 to E16.5 and 
reappears at the beginning of folliculogenesis, being 
expressed in granulosa, thecal and luteal cells of the 
adult ovary (see above, Ikeda et al., 1993; Hanley et 
al., 1999; Hanley et al., 2001). 
During embryonic development, SF-1 expression is 
tightly temporally and spatially controlled. An E-
box-binding site within the basal promoter of SF-1 
gene has been described to be critical for SF-1 
expression (Nomura et al., 1995). The transcription 
factor POD1/capsulin has been reported to repress 
SF-1 expression in the gonad through binding to this 
E-box (Tamura et al., 2001; Cui et al., 2004), 
whereas WT1 plays a role as a positive regulator of 
SF-1 expression in the developing gonad (Wilhelm 
and Englert, 2002), like the LIM homeobox gene 
Lhx9 (Birk et al., 2000). Interestingly, genetic and 
molecular evidence shows that the transcription co-
factor CITED2 interacts with WT1 to promote SF-1 
expression in the AGP before the separation between 
gonad and adrenal cortex, a critical time during 
embryogenesis (Val et al., 2007). 
Recently, Morohashi and collaborators have 
identified one intergenic and three intragenic 
(intronic) enhancers, which are essential for tissue 
and SF-1 stage specific expression in mice. Those 
tissue-specific enhancers direct SF-1 expression to 
the fetal adrenal (Fetal Adrenal Enhancer, fAdE, 
localized to intron 4) (Zubair et al., 2006), the 
developing pituitary and adult gonadotropes 
(Pituitary Gonadotrope Enhancer, PGE, localized to 
intron 6) (Shima et al., 2008), the developing 
diencephalon and adult VMH (VMH Enhancer, 
VMHE, localized to intron 6, upstream of PGE) 
(Shima et al., 2005) and fetal Leyding cells (Fetal 
Leydig cell Enhancer, FLE; intergenic, located 
upstream of the transcriptional start site) (Shima et 
al., 2012). Although the activity of these enhancers 
has been established only in mice, all enhancers, like 
the basal promoter, are conserved among the 
different animal species (Shima et al., 2012). 
Localisation 
SF-1 is constitutively localized in the nucleus where 
it acts as a DNA-binding transcription factor. 
Interestingly, it has been described that it also moves 
inside the nucleus according to the status of its post-
translational modifications (Chen et al., 2004; Fan et 
al., 2004). SUMOylation seems to repress SF-1 
activity as the mutations of its SUMO acceptor sites 
K119 and K194 enhance SF-1 - driven gene 
activation. It has been proposed that SUMO-
conjugated SF-1 localizes to the PML nuclear 
speckles, where SF-1 is sequestered from 
nucleoplasm and is associated with repressors, like 
DP103 (Lee et al., 2005; Wang et al., 2013). SF-1 
can also be acetylated at the KQQKK sequence in 
the Ftz-F1 box and activated by the histone 
acetyltransferase p300 (Chen et al., 2005). 
Following cAMP stimulation, SF-1 spreads out into 
discrete transcriptionally active foci containing RNA 
polymerase II, p300 (Chen et al., 2005) and the 
ubiquitous histone acetyltransferase GCN5 (Fan et 
al., 2004). It has been hypothesised that SF-1 is 
recruited to those transcriptionally active loci as a 
result of physical interactions with co-regulators like 
p300 and GCN5. Furthermore, when SF-1 is 
acetylated by p300 at the FTZ-F1 domain, its 
binding to p300 increases. It seems that acetylation 
is involved in retaining SF-1 in the transcriptionally 
active nuclear foci, thus promoting SF-1 - mediated 
target gene transcription (Chen et al., 2005). Neither 
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phosphorylation at Ser 203 (Hammer et al., 1999) 
nor ubiquitination (Chen et al., 2007) appear to 
change or affect SF-1 distribution. Recently, it has 
been shown that SF-1 is also located in the 
centrosome. Immunofluorescence analysis revealed 
that it colocalizes with the centrosome marker γ-
tubulin in mouse adrenocortical Y1 and mouse 
testicular Leydig MA-10 cells (Lai et al., 2011). 
Sucrose gradient fractionation studies in Y1 cells 
have confirmed immunofluorescence results (Lai et 
al., 2011). A centrosome localization signal (CLS) 
has also been identified by deletion analysis and 
localized to aa 348-367 (Lai et al., 2011). Moreover, 
SF-1 centrosomal localization results to be 
independent from microtubule (MT) transportation, 
as after MT depolymerization SF-1 still colocalizes 
with acetylated tubulin (Wang et al., 2013). 
Function 
SF-1 as a master regulator of gene expression in 
steroidogenic cells 
SF-1 was identified as a key factor that regulates the 
expression of several steroidogenic enzymes in a 
tissue-specific manner (Lala et al., 1992; Morohashi 
et al., 1992). In steroidogenic tissues, SF-1 regulates 
steroidogenic pathways including genes encoding 
cytochrome P450 enzymes as CYP11A1 (Chau et 
al., 1997), CYP17A1 (Bakke et al., 1995), 
CYP21A2, CYP11B1 (Morohashi et al., 1993), 
CYP11B2 (Bassett et al., 2002), 3β-hydroxysteroid 
dehydrogenase (3βHSD) (Leers-Sucheta et al., 
1997), steroidogenic acute regulatory protein (StAR) 
(Sugawara et al., 1996). Other evidence shows that 
SF-1 regulates many genes involved in development 
and steroidogenic function (reviewed in Schimmer 
and White, 2010). SF-1 is generally considered as an 
activator of gene expression, but it can act as a 
negative regulator of the type 4 adenylyl cyclase and 
of CYP11B2 (Rui et al., 2008; Ye et al., 2009). SF-
1 also regulates genes involved in sex determination 
and development of reproductive tissues including 
DAX1, AMH, SOX9, SRY (Kawabe et al., 1999; De 
Santa Barbara et al., 1998; De Santa Barbara et 
al.,2001; Sekido et al., 2008). Thus, SF-1 plays a 
central role in development and function of the 
steroidogenic and reproductive systems. 
Some SF-1-interacting proteins (positive and 
negative cofactors) are expressed in a tissue-specific 
manner whereas others are more widely expressed. 
Further studies are necessary to better understand 
how these cofactors could contribute to control cell- 
and time-specific expression of SF-1-dependent 
genes. Interactions between SF-1 and DAX-1 
represent a particular interest (Ikeda et al., 1996). 
DAX1, an X-linked gene that encodes a repressor of 
steroidogenic gene expression, modulates the 
activity of SF-1 (Lalli et al., 1998). Mutations in 
DAX-1 cause X-linked adrenal hypoplasia congenita 
and hypogonadotrophic hypogonadism, phenotypes 
similar to those seen with NR5A1 mutations 
(reviewed in Lalli, 2003 and Lalli, 2014). 
Putative phospholipid ligands, post-translational 
modifications (phosphorylation, sumoylation, 
acetylation), epigenetic gene expression regulation 
and gene dosage (see below) can influence SF-1 
transcriptional activity, subnuclear localization 
and/or DNA-binding activity (reviewed in Hoivik et 
al., 2010; Lalli, 2010; Schimmer and White, 2010). 
By different genomic approaches, multiple levels of 
regulation exerted by SF-1 dosage on transcriptome, 
and more recently on its cistrome have been explored 
(Doghman et al., 2007; Doghman et al., 2013). These 
recent studies have shown that SF-1 regulates 
distinct categories of genes in adrenocortical cancer 
cells according to its dosage. Moreover, the binding 
of SF-1 to chromatin sites in condition of different 
SF-1 dosage correlates with differential regulation of 
gene expression (Doghman et al., 2013). 
Transcriptional profiling revealed that SF-1 dosage-
dependent genes are involved in lipid and steroid 
metabolism, but also in apoptosis, cell cycle 
regulation, cell adhesion and transcriptional 
regulation (reviewed in Lalli et al., 2013). Other 
recent studies show that SF-1 knockdown affects the 
expression of a large number of transcripts that are 
not only involved in steroid synthesis (Schimmer et 
al., 2011). A recent study suggested that SF-1 may 
be involved in glucose metabolism by regulating 
genes of the glycolytic pathways (Baba et al., 2014) 
even if this was not observed in other studies 
(Schimmer et al., 2011; Doghman et al., 2013). 
From Knock-out mice models to human 
mutations phenotype: Evidence of the key role of 
SF-1 in differentiation and development. 
Studies of both complete and tissue-specific 
knockout mice have demonstrated that SF-1 is a key 
factor for the development of the adrenal glands, 
gonads, ventromedial hypothalamus and in pituitary 
gonadotropes functions (Luo et al., 1994; Sadovsky 
et al., 1995; Shinoda et al., 1995; Ikeda et al., 1995; 
Zhao et al., 2001). To characterize the role of SF-1 
in different tissues and to distinguish between the 
direct and secondary effects of SF-1 deficiency, 
Keith Parker's laboratory developed mice models 
that are specifically deleted for Sf-1 in gonadotrope 
cells, gonads and VMH by using the Cre/lox 
approach (Jeyasuria et al., 2004; Pelusi et al., 2008; 
Zhao et al., 2008). 
Role in adrenal and gonads 
Sf-1 null mice lack adrenal glands and gonads and 
die from adrenal insufficiency within the first week 
after birth. Mice lacking Sf-1 show early adrenal and 
gonadal development that regresses by apoptosis 
between E11.5 and E12.5 (Luo et al., 1994; 
Sadovsky et al., 1995) indicating that Sf-1 is 
essential for early development and maintenance of 
adrenal and gonadal primordia. 
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SF-1 knockout mice exhibited male-to-female sex 
reversal of their internal and external genitalia. Since 
their gonads regressed before male sexual 
differentiation normally occurs, the internal and 
external urogenital tracts of SF-1 KO mice are 
female irrespective of genetic sex. Absence of testes 
in homozygous mutant male mice precludes MIS 
(Müllerian inhibiting substance) and androgen 
production, which accounts for the observed 
phenotypes (Luo et al., 1994; Sadovsky et al., 1995). 
Heterozygous Sf-1 null mice have decreased adrenal 
volume associated with impaired corticosterone 
production in response to stress and present smaller 
testes (Bland et al., 2000). These mice also present a 
defect in compensatory growth in the remaining 
adrenal following unilateral adrenalectomy, 
indicating that SF-1 is required for cell proliferation 
in steroidogenic tissue (Beuschlein et al., 2002). 
Differences in adrenal development between 
heterozygous animals and their wild-type littermates 
were more evident during embryonic development 
than postnatally due to a partial compensation of 
adrenal function after birth (Bland et al., 2004). 
Thus, a difference between the capacity of the 
adrenal gland and gonad to compensate for partial 
loss of SF-1 function might be one of the 
mechanisms explaining why the gonadal phenotype 
is more marked than the adrenal phenotype in 
humans with heterozygous NR5A1 mutations (see 
Implications in pathology). 
Male gonad-specific Sf-1 KO mice display 
hypoplastic testes observed starting from early 
developmental stages associated with an impaired 
spermatogenesis which makes the animals sterile. 
Moreover, in this model, the testes do not descend 
(cryptorchidism), demonstrating an in vivo 
important role of SF-1 in hormonal production for 
virilization and testes descent (Jeyasuria et al., 
2004). Sf-1 KO ovaries were indistinguishable from 
wild-type during embryogenesis and at birth, but 
adult females were sterile. In the ovaries, the total 
number of ovarian follicles is decreased and corpora 
lutea are lacking, indicating an important role for SF-
1 in ovulation (Jeyasuria et al., 2004). SF-1 is then 
essential for normal gonadal function in both male 
and female mice. 
Role in anterior pituitary, VMH and spleen 
The consequences of SF-1 KO at the level of 
pituitary and hypothalamus have important impacts 
on their target organs. Indeed, the pituitaries of SF1 
knockout mice have markedly decreased expression  
of both pituitary gonadotropins [luteinizing hormone 
(LH) and follicle-stimulating hormone (FSH)] and 
have impaired expression of many target genes that 
regulate gonadal steroidogenesis (Ingraham et al., 
1994; Shinoda et al., 1995). However, GnRH 
treatment of SF-1 knockout mice induced pituitary 
expression of LH and FSH, indicating that 
gonadotropes can express putative SF-1 target genes 
in the absence of SF-1 (Ikeda et al., 1995). 
The pituitary-specific Sf-1 KO mice have markedly 
decreased levels of LH and FSH and exhibit 
hypoplastic gonads, impaired secondary sexual 
development and are sterile. Administration of 
gonadotropins partially rescues the gonadal 
phenotype. All these studies establish a primary role 
for SF-1 in gonadotrope function in the pituitary in 
mice (Zhao et al., 2001). 
In the brain of SF-1 KO mice, the region of the 
ventromedial hypothalamus is disorganized and does 
not show its characteristic structures. The VMH is a 
hypothalamic region linked to feeding and appetite 
regulation and female reproductive behavior 
(Shinoda et al., 1995; Ikeda et al., 1995; Zhao et al., 
2001). SF-1 is the only gene that is specifically and 
exclusively expressed in the VMH. It is noteworthy 
that SF-1 KO mice that are maintained alive by 
adrenal transplantation exhibit late onset obesity 
suggesting a potential role of SF-1 in regulation of 
food intake (Majdic et al., 2002). 
The nestin promoter, which is active in the CNS, was 
used to create a brain-specific Sf-1 KO micenCre; F/- 
model equivalent of a VMH-specific knockout 
(Zhao et al., 2008). The organization of VMH 
neurons is dramatically changed in this model, and 
mice also present an increased anxiety-like behavior 
and a decreased locomotor activity (Zhao et al., 
2008). Moreover, Sf-1 KOnCre; F/- female mice have 
impaired follicle development, fertility and sexual 
behaviors and normal body weight, delineating an 
important role for SF-1 expressed in the VMH in 
female reproductive function, independently of 
energy balance regulation (Kim et al., 2010). To 
distinguish between the direct metabolic roles of SF-
1 and its developmental side effects, an alternative 
mouse model named postnatal VMH-specific SF-1 
KO was generated in which SF-1 is specifically 
deleted after completion of VMH development using 
CamKII-Cre, a postnatally expressing Cre line (Kim 
et al., 2011). These postnatal VMH-specific Sf-1 KO 
animals display a diet-induced obesity and revealed 
that SF-1 is required for normal energy homeostasis 
by modulating energy expenditure especially in 
high-fat diet condition (Kim et al., 2010). Although 
SF-1-expressing neurons do not represent all 
neurons within the VMH, many studies establish that 
SF-1 neurons in the VMH are  
essential for normal energy homeostasis, particularly 
in regulation of energy expenditure (reviewed in 
Choi et al., 2013). 
It has been shown that disruption of SF-1 also causes 
developmental abnormalities in spleen tubular 
structure and impaired clearance by the splenic 
vascular system (Morohashi et al., 1999). Similar 
defects have been observed in mice with disruption 
of the mouse polycomb 33 gene (M33) and suggest 
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an interaction between M33 and SF-1 in splenic 
development (Katoh-Fukui et al., 2005). 
SF-1 involvement in human disease 
Genetic evidence for the essential role of SF-1 in 
endocrine development also comes from studies on 
human patients. These genetic mutations provide 
insights into the function of SF-1 and the 
mechanisms of XY sex reversal, ovarian anomalies 
and adrenal failure (reviewed in Lin and Achermann, 
2008). 
More than 70 human SF-1 mutations have been 
described, with most of them found in a 
heterozygous state and only a few found in 
homozygote or compound heterozygote state (see 
Mutation). In humans, the first description of a 
heterozygous loss-of-function SF-1 mutation 
(G35E) was made in a patient with adrenal failure 
and complete 46,XY sex-reversal, closely matching 
the phenotype of Sf-1 null mice (Achermann et al., 
1999). Afterwards, several other patients have been 
described presenting variable degrees of gonadal and 
adrenal dysgenesis caused by SF-1 
haploinsufficiency, while only one homozygous SF-
1 mutation has been described (R92Q) in a patient 
with adrenal hypoplasia and 46,XY sex-reversal 
(Achermann et al., 2002). In several cases, SF-1 
haploinsufficiency has been shown to be associated 
with isolated gonadal dysgenesis or ovarian 
insufficiency, while only one case has been 
described of a prepubertal girl with adrenal 
insufficiency and apparently normal ovaries 
(Biason-Lauber et al., 2000). It appears that a species 
difference exists in the sensitivity to SF-1 dosage. In 
fact, while adrenals and gonads are both affected by 
Sf-1 haploinsufficiency in mice, in humans the great 
majority of heterozygote SF-1 mutations are 
associated with disorders of sex development (Lin et 
al., 2007), premature ovarian failure (Lourenço et al., 
2009) or male infertility (Bashamboo et al., 2010) 
rather than adrenal development (see Mutation and 
Implication in pathology). 
Recently, novel SF-1 mutations were identified in 
patients with 46,XY DSD and adrenal insufficiency. 
In vitro analysis revealed that these SF-1 mutations 
affect not only steroidogenesis but also transcription 
of the BDNF gene that is involved in energy balance 
(Malikova et al., 2014). However, in contrast to 
mice, consequences on weight were not found in 
humans with SF-1 mutations and further studies are 
necessary to confirm the impact of SF-1 on body 
weight regulation in human. 
A recent study describes a clinical phenotype of 
severe 46,XY-DSD with asplenia, caused by a novel 
homozygous SF1 mutation (R103Q) suggesting that 
SF-1 is required for spleen development in humans 
(Zangen et al., 2014). 
SF-1 dosage as a key regulator of adrenocortical 
growth and of tumorigenesis 
The critical role of SF-1 as a developmental 
regulator became evident by the analysis of the 
phenotype of Sf-1 KO mice (see above). The role for 
Sf-1 gene dosage in the development of adrenals is 
demonstrated by the finding that Sf-1 heterozygous 
mice have hypoplastic adrenals, with a decreased 
corticosterone and increased ACTH plasma levels, 
especially after stress (Bland et al., 2000). Also in the 
adult mouse Sf-1 dosage is critical for compensatory 
adrenal growth following unilateral adrenalectomy 
(Beuschlein et al., 2002). 
The function of SF-1 in the regulation of 
adrenocortical growth has a particular relevance to 
understand the mechanisms of adrenocortical 
tumorigenesis. Important input came from pediatric 
adrenocortical tumors studies. These tumors are 
particularly frequent in southern Brazil and are 
associated with the presence of the germline R337H 
TP53 mutation, NR5A1 copy number gain/gene 
amplification and SF-1 protein overexpression 
(Ribeiro et al., 2001; Figueiredo et al., 2005; 
Pianovski et al., 2006; Letouzé et al., 2012). 
Subsequent studies involving both a human 
adrenocortical cell line with inducible SF-1 
overexpression and a transgenic mouse model 
bearing multiple copies of the Sf-1 gene showed that 
an increased SF-1 dosage activates adrenocortical 
cell proliferation and induces adrenocortical 
neoplasia (Karpova et al., 2005; Doghman et al., 
2007). Moreover, the transcriptional activation 
function (AF2 domain) of SF-1 is necessary for its 
role in adrenocortical cell proliferation. 
Interestingly, those tumors develop in the 
subcapsular region of the Sf-1 transgenic adrenal 
glands and express the gonadal markers Gata4 and 
AMH, derived most probably from undifferentiated 
adrenogonadal precursors (Looyenga and Hammer, 
2006). Transcriptome analysis revealed that SF-1 
regulates new and distinct categories of gene 
involved in multiple functions according to its 
dosage (Doghman et al., 2013) (see above). 
Altogether, it appears that SF-1 dosage plays an 
important role during adrenal development and 
tumorigenesis. 
Role of SF-1 in embryonic stem (ES) cells 
differentiation 
The role of SF-1 in stem cells differentiation into 
steroid-producing cells was first investigated in 1997 
by Crawford and colleagues (Crawford et al., 1997). 
They reported that the forced expression of SF-1 
directed mouse ES cells into the steroidogenic cell 
lineage, although the steroidogenic capacity of these 
cells was very limited. Upon SF-1 transfection, 
human mesenchymal stem cells (MSC) were shown 
to be successfully converted into steroidogenic cell 
lineage appearing to be glucocorticoid- rather than 
testosterone-producing cells (Yawaza et al., 2006). 
Moreover, Gondo et al., reported that steroid 
hormone production was observed for more than 112 
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Atlas Genet Cytogenet Oncol Haematol. 2015; 19(8) 528 
 
d when bone marrow-derived MSC were infected 
with SF-1 by an adenoviral vector (Gondo et al., 
2008). Interestingly introduction of LRH1 (Liver-
specific receptor, NR5A2), another member of the 
NR5A family, resulted in differentiation of human 
MSCs into steroidogenic cells (Yawaza et al., 2009). 
In 2011, Yazawa et al., reported a method for 
differentiating mouse ES cells into steroid-
producing cells through tetracycline-controlled 
transcriptional activation of SF-1 (Yazawa et al., 
2011). 
It has been demonstrated that human ES/iPS 
(induced Pluripotent Stem) cells can be 
differentiated into steroid-producing cells by first 
inducing them to differentiate into the mesodermal 
lineage and then introducing SF-1 (Sonoyama et al., 
2012). The steroidogenic cells obtained expressed 
mRNAs encoding adrenocortical or gonad-specific 
steroidogenic enzymes and produced a wide variety 
of steroid (Sonoyama et al., 2012). All these findings 
indicate that SF-1 could work as a differentiating 
factor for the steroidogenic differentiation of 
multipotent stem cells and open new perspectives for 
future regenerative therapy. 
Mutations 
Studies carried out on human patients provided 
genetic evidence for the pivotal role of SF-1 in 
endocrine development. Several SF-1 mutations 
have been described in humans and are associated 
with a wide variety of human reproductive 
phenotypes, like 46,XY disorders of sex 
development (DSD), hypospadias, anorchia, male 
infertility or primary ovarian insufficiency in women 
and adrenal failure (reviewed in Lin and Achermann, 
2008; Ferraz-de-Souza et al., 2011; Human Gene 
Mutation Database). Several of these genetic 
alterations are represented by heterozygous 
nonsense or frameshift mutations which alter RNA 
stability through nonsense-mediated decay or 
produce a truncated non-functional protein 
(reviewed in Lin and Achermann, 2008). Other 
genetic alterations are present as nucleotide 
polymorphisms or deletions.  
Several novel heterozygous missense mutations 
identified provide interesting insights into SF-1 
structure-function correlation. As described below, 
most of those missense mutations lie within the 
primary or accessory DBD affecting highly-
conserved aminoacid residues (reviewed in Lin and 
Achermann, 2008). These genetic alterations 
interfered with DNA binding and inhibited 
transcriptional activation in transient gene 
expression assays.  
The earliest studies on NR5A1 mutations were based 
on single case reports (Achermann et al., 1999; 
Achermann et al., 2002). They focused on the rare 
group of 46,XY females exhibiting primary adrenal 
failure, severe gonadal dysgenesis and persistence of 
Mülleran structures (a phenotype resembling Sf-1 
null knockout mice). The first patient showed a 
heterozygous de novo G35E mutation which disrupts 
the P-box primary DNA-binding motif within the 
first zinc finger of SF-1 DBD (see Protein 
description), thus resulting in diminished target gene 
binding and transactivation (Achermann et al., 1999; 
Ito et al., 2000a; Tremblay et al., 2003). The second 
patient exhibited a homozygous R92Q mutation 
within the A-box (see Protein description), resulting 
in a variable and partial loss of SF-1 activity 
(Achermann et al., 2002).  
Other reported mutations were shown to impair 
transcriptional activity through abnormal DNA 
binding (V15M, M78I, G19S), perturbed sub-
nuclear localization (V15M, M78I, as well as 
another mutation in the DBD, C33S, Köhler et al., 
2008) or by disrupting the putative ligand-binding 
pocket (L437Q) (Lin et al., 2007). Another mutation 
affecting the proximal part of the SF-1 LBD is 
R255L, a de novo heterozygous change identified in 
a girl showing primary adrenal insufficiency at 14 
months of age (Biason-Lauber and Schoenle, 2000). 
The mutant SF-1 protein was shown to be 
transcriptionally inactive, but without a dominant 
negative effect.  
Further, in-frame deletions and frameshift and 
missense mutations have been detected in four 
families with histories of both 46,XY DSD and 
46,XX primary ovarian insufficiency and in 2 of 25 
patients with sporadic ovarian insufficiency 
(Lourenço et al., 2009). Functional studies showed 
that those mutations substantially impaired SF-1 
transactivation activity. One of the mutation 
identified by Lourenço et al. in the LBD is D293N. 
The mutated protein partly activated both CYP11A1 
and CYP19A1 promoters (Lourenço et al., 2009). 
Homozigosity for D293N caused either 46, XY 
complete gonadal dysgenesis or 46, XY DSD, 
suggesting a pivotal role of this domain in 
modulating male sex differentiation. 
NR5A1 mutations can affect also the hinge region of 
the protein (see Protein structure). The first mutation 
discovered in the hinge region was G146A 
(WuQiang et al., 2003). The mutated protein shows 
slightly diminished transactivation activity on the 
CYP11A promoter and the CYP19 promoter II. 
However, the mutation does not alter protein 
expression or stability and does not display dominant 
negative effect.  
Recent studies in patients with novel NR5A1 
mutations have shown no clear genotype-structure-
function-phenotype correlation (Camats et al., 
2012). Thus, further investigation is necessary to 
better understand the broad range of clinical 
manifestations produced by SF-1 mutations. 
Implicated in 
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SF-1 expression in prostate cancer 
Recently, it has been reported that SF1 is expressed 
in prostate cancer cells but not in normal prostate. 
SF-1 expression stimulates local and autonomous 
steroid production necessary to induce proliferation 
and survival that contribute to aggressive prostate 
cancer (Lewis et al., 2014). 
SF-1 overexpression and adrenal 
tumorigenesis 
Important insights into the key role of SF-1 dosage 
came from pediatric adrenocortical tumors analysis. 
Using comparative genomic hybridization (CGH) 
and SNP array profiling, a high frequency of 
chromosomal aberrations and amplification of 9q33-
q34 region, harboring the SF-1 gene, emerged as the 
most consistent finding in a majority childhood 
adrenocortical tumors (Figueiredo et al., 1999; 
Figueiredo et al., 2005; Pianovski et al., 2006; 
Letouzé et al., 2012). SF-1 overexpression has been 
shown to increase proliferation of human 
adrenocortical cells, and to induce adrenocortical 
tumors in Sf-1 transgenic mice (Doghman et al., 
2007) (see above). Further studies have shown that 
the levels of SF-1 expression represent a stage-
independent prognostic indicator in patients with 
adrenocortical cancer (Sbiera et al., 2010). SF-1 
dosage is then considered as a critical factor in 
adrenocortical tumorigenesis (reviewed in Lalli, 
2010). 
SF-1 expression in endometriosis 
SF-1 is expressed in endometriotic cells whereas it is 
not usually detected in normal endometrium and can 
exert a role in the pathogenesis of endometriosis 
(Xue et al., 2007; reviewed in Bulun et al., 2009). 
SF-1 expression leads to an aberrant activation of 
StAR and CYP19 genes expression and to an 
increase of the endogenous synthesis of estrogen 
within endometriotic tissue, a key causative factor in 
the disease. This aberrant expression seems to be 
explained by modifications in the regulation of SF-1 
expression by DNA methylation of CpG islands in 
the promoter, intron 1, and exon 2/intron 3 regions 
(Xue et al., 2014).  
46 XY, development of sex disorders 
(DSD) 
Note 
Heterozygous NR5A1 mutations emerge as a 
relatively frequent finding in patient with 46,XY 
DSD from typical to severe phenotype, but without 
adrenal insufficiency. The patients present a 
phenotype of ambiguous or female external genitalia 
at birth and small inguinal testes. Müllerian 
structures may be present or absent, and Wolffian 
structures are often seen. There is a significant 
biochemical evidence of partial gonadal dysgenesis 
with impaired androgen synthesis, that contributes to 
the phenotype, as shown by low levels of 
testosterone, inhibin β and AMH and an elevation of 
FSH (reviewed in Lin and Achermann, 2008). 
NR5A1 mutations have also been detected in 46, XY 
patients with severe hypospadia and small inguinal 
testes due to partial dysgenesis and /or a reduced 
androgen synthesis (Lin et al., 2007). SF-1 was also 
considered as a candidate gene for bilateral 
anorchidia based on the study of a cohort of 24 boys 
where one boy carried a heterozygous NR5A1 
mutation. He presented one absent testis, one very 
small testis with undectable AMH in early infancy, 
and later a testis atrophy in childhood (Philibert et 
al., 2007). However the patient's twin brother who 
harbored the same mutation underwent normal 
puberty suggesting that, despite incomplete 
penetrance of NR5A1 mutations, SF-1 could 
participate in maintaining the testis.  
A study identified heterozygous NR5A1 mutations, 
localized in the hinge region and proximal LBD of 
the protein, associated with spermatogenic failure 
(from moderate oligospermia to azoospermia) in 
healthy men, widening the range of gonadal 
phenotypes associated with NR5A1 mutations 
(Bashamboo et al., 2010). 
Adrenal insufficiency 
Given the central role of SF-1 in adrenal 
development and steroidogenesis, several studies 
have looked for NR5A1 mutations in children and 
adults with primary adrenal insufficiency. Only few 
cases have been described of NR5A1 mutations that 
also produce adrenal insufficiency in addition to 
gonadal defects (Achermann et al., 1999; 
Achermann et al., 2002; Malikova et al., 2014). A 
single case of a prepubertal girl where adrenal 
insufficiency was associated with apparent normal 
ovarian development has been reported (Biason-
Lauber and Schoenle, 2000).  
In another study, no NR5A1 mutations were 
identified in a small cohort of girls diagnosed with 
adrenal hypoplasia (Lin et al., 2006).  
 
Similarly, no significant NR5A1 changes were 
found in boys affected by adrenal hypoplasia without 
DAX1 mutations (Lin et al., 2006). Thus, NR5A1 
mutations seem not to be a common cause of primary 
adrenal failure in boys without reproductive 
dysfunction or 46,XY DSD. 
Primary ovarian insufficiency (POI) 
Note 
NR5A1 mutations have been identified in familial 
and sporadic forms of 46,XX primary ovarian 
insufficiency (Lourenço et al., 2009). These 46XX 
patients presented either primary or secondary 
amenorrhea at variable ages. Primary gonadal failure 
was associated with elevated LH and FSH and low 
estrogen levels. These NR5A1 mutations, detected in 
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subjects with anomalies of ovarian development and 
function, are associated with an impairment of 
transactivation on the CYP11A1 and CYP19A1 
promoters. Detection of NR5A1 mutations in 46, XX 
women with ovarian failure shows that SF-1 is an 
important factor in ovarian development and 
function in humans. 
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